Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays
The Abbott ID NOW<sup>TM</sup> COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOW<sup>TM</sup> COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication.
Authors
- Yin Li (ORCID: https://orcid.org/0000-0002-0929-4661)
- Christopher W. Woods (ORCID: https://orcid.org/0000-0001-7240-2453)
- Maria D. Iglesias-Ussel (ORCID: https://orcid.org/0000-0002-3679-9681)
- S Geller (ORCID: https://orcid.org/0000-0003-3903-6943)
- Kian Merchant‐Borna (ORCID: https://orcid.org/0000-0002-6643-1597)
- Jack Anderson
- Gudrun Strauß
- Aaron S. Weinberg
- Manish Jain (ORCID: https://orcid.org/0000-0002-7263-9829)
- Aleah Bowie (ORCID: https://orcid.org/0000-0003-3098-6862)
- Valentine M. Ebuh
- Lawrence P. Park
- Joby Thoppil (ORCID: https://orcid.org/0000-0002-3722-3369)
- Anand Patel (ORCID: https://orcid.org/0000-0001-6576-4579)
- José F. Cardona
- Patrick Dennis
- Mark M. McKenzie
- A. Siegel
Institutions
- Duke University (US)
- Abbott (United States) (US)
- Technologies pour la Santé (FR)
- Centennial Medical Group (US)
- Duke Institute for Health Innovation (US)
- Abbott (Germany) (DE)
- Carbon180 (US)
- Great Lakes Clinical Trials (US)
- University of Rochester (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Microbiology Spectrum
- Published
- 2025-02-11
- DOI
- https://doi.org/10.1128/spectrum.02033-24
- Citations
- 2
- Primary Topic
- SARS-CoV-2 detection and testing
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Abbott Diagnostics